Systematic review shows serum irisin levels are lower in cancer patients, indicating its potential role as a diagnostic biomarker.
Irisin influences key cancer-related processes such as cell proliferation, apoptosis, angiogenesis, and metastasis. This review aimed to evaluate serum irisin's potential in cancer diagnosis, prognosis, and treatment monitoring. Databases including Scopus, PubMed, Cochrane, and others were searched. Studies comparing serum irisin in cancer patients and healthy individuals were assessed using Joanna Briggs Institute criteria. Nine studies showed significantly lower irisin levels in cancer patients (SMD: -1.16, p < 0.0001), especially in hepatocellular and bladder cancers. Reduced serum irisin may serve as a diagnostic cancer biomarker, though its utility varies by cancer type and requires further research. CRD420250650210.
No takes yet. Share an insight, caveat, or question.
Mohandas et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: